Details of the Drug | DrugMAP

General Information of Drug (ID: DMB5N7B)

Drug Name

Modakafusp alfa

Synonyms

TAK-573

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1/2	[1]
Multiple myeloma	2A83	Phase 1/2	[2]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D1B3VP

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT04157517) An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05590377) A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.